Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Results of the Phase II GeparNuevo trial

Evandro de Azambuja • 11 Jun 2021
ASCO 2021
Breast Cancer Durvalumab
GeparNuevo

Evandro de Azambuja, MD, PhD, L’Universite Libre de Bruxelles, Brussels, Belgium, discusses the results of the GeparNuevo trial (NCT02685059), which looks at taxane-anthracycline chemotherapy with and without addition of durvalumab immunotherapy for triple negative breast cancer. After a follow up of 43 months, it was found that patients who were treated with chemotherapy/immunotherapy had a better invasive disease-free survival (IDFS), distant disease-free survival (DDFS) and overall survival. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

More from Evandro de Azambuja

APHINITY: OS in HER2-positive breast cancer
2:58
APHINITY: OS in HER2-positive breast cancer
Evandro de Azambuja • 16 May 2025
De-escalation and escalation strategies for HER2+ breast cancer
12:16
De-escalation and escalation strategies for HER2+ breast cancer
Evandro de Azambuja • 23 May 2024
Early response and long-term outcomes in the CLEOPATRA trial
2:29
Early response and long-term outcomes in the CLEOPATRA trial
Evandro de Azambuja • 23 May 2024
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer
2:01
Tumor infiltrating lymphocytes (TILs) as a predictive biomarker in breast cancer
Evandro de Azambuja • 12 Sep 2022

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals